A Phase 2 Open-label Study Evaluating Dosimetry Randomized Dose Optimization Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants with PSMA PET-Positive Castration-Resistant Prostate Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Prostate Cancer
    Prostate
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male
  • Other Inclusion Criteria:
    1. Serum PSA progression consisting of two consecutive increases in PSA measured at least 1 week apart. The minimal baseline value is 2.0 ng/mL.
    2. Progression of bone disease defined by PCWG3 as evaluable disease or new bone lesions by bone scan.
    3. Identification of new soft tissue or bone lesions on PSM

You may not be eligible for this study if the following are true:

    1. Superscans by nuclear medicine/99mTc bone scan
    2. A known malignancy that is progressing or has required active treatment within the past 3 years other than CRPC, which is expected to alter life expectancy or may interfere with CRPC disease assessment.
    3. Known active uncontrolled or symptomatic central nervous system (CNS) metastases and/or progressive carcinomatous meningitis, or progressive leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.